What is NovoPath?
NovoPath, Inc. operates as a key player in the Lab Information Systems (LIS) sector, catering to Anatomic, Clinical, and Molecular Pathology, Genetic Testing, and Clinical Trials markets. Headquartered in Princeton, NJ, the company's mission is to deliver innovative solutions and services that enhance workflow efficiency, minimize human error, and ensure the accuracy of diagnostic outcomes for improved patient safety and confidentiality. Its client base spans national and regional reference labs, university teaching hospitals, and community hospitals, highlighting its broad impact across the diagnostic laboratory landscape.
How much funding has NovoPath raised?
NovoPath has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for NovoPath?
With the recent influx of capital and its designation as a large-scale late-stage funding event, NovoPath is strategically positioned for accelerated expansion and technological advancement. This substantial backing is expected to fuel further innovation in its LIS offerings, potentially enabling the company to broaden its market reach and enhance its service capabilities. The focus on improving diagnostic precision and patient safety suggests a continued commitment to addressing critical needs within the healthcare ecosystem, positioning NovoPath for sustained growth and influence in the pathology and genetic testing arenas.
See full NovoPath company page
